SCHEMBL23321663

SCHEMBL23321663

C=C(C)COCCCCCCCCCCCCCCCCCCCC[Si](Cl)(Cl)Cl

nearest known ligand 0.37

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23321998 1.00 CES2 (0.37) CES2
SCHEMBL23321788 1.00 CES2 (0.37) CES2
SCHEMBL23321718 1.00 CES2 (0.37) CES2
SCHEMBL23321576 1.00 CES2 (0.37) CES2
SCHEMBL23321960 1.00 CES2 (0.37) CES2
SCHEMBL23321810 1.00 CES2 (0.37) CES2
SCHEMBL23321662 1.00 CES2 (0.37) CES2
SCHEMBL23321770 1.00 CES2 (0.37) CES2
SCHEMBL23322208 1.00 CES2 (0.37) CES2
SCHEMBL23321671 1.00 CES2 (0.37) CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3819301-B1 PREPARATION OF ORGANOSILICON COMPOUND HAVING (METH)ACRYLOYLOXY GROUP SHINETSU CHEMICAL CO (JP) 2025-08-06 EP disclosed
US-11377455-B2 Preparation of organosilicon compound having (meth)acryloyloxy group SHIN-ETSU CHEMICAL CO., LTD. (JP) 2022-07-05 US disclosed
US-20210139515-A1 Preparation of Organosilicon Compound Having (Meth)acryloyloxy Group SHIN-ETSU CHEMICAL CO., LTD. (JP) 2021-05-13 US disclosed
EP-3819301-A1 PREPARATION OF ORGANOSILICON COMPOUND HAVING (METH)ACRYLOYLOXY GROUP Shin-Etsu Chemical Co., Ltd. (JP) 2021-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11377455-B2 Preparation of organosilicon compound having (meth)acryloyloxy group H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MMAB, ACR CES2 792/4885
US-20210139515-A1 Preparation of Organosilicon Compound Having (Meth)acryloyloxy Group H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MMAB, ACR CES2 774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.